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Virus captureding to the HIV-1 envelope spike (Env), the conserved N-heptad repeat (NHR)
region of gp41 forms a coiled-coil that is a precursor to the fusion reaction. Although it has been a target of
drug and vaccine design, there are few monoclonal antibody (mAb) tools with which to probe the
antigenicity and immunogenicity speciﬁcally of the NHR coiled-coil. Here, we have rescued HIV-1-
neutralizing anti-NHR mAbs from immune phage display libraries that were prepared (i) from b9 rabbits
immunized with a previously described mimetic of the NHR coiled-coil, N35CCG-N13, and (ii) from an HIV-1
infected individual. We describe a rabbit single-chain Fv fragment (scFv), 8K8, and a human Fab, DN9, which
speciﬁcally recognize NHR coiled-coils that are unoccupied by peptide corresponding to the C-heptad repeat
or CHR region of gp41 (e.g. C34). The epitopes of 8K8 and DN9 were found to partially overlap with that of a
previously described anti-NHR mAb, IgG D5; however, 8K8 and DN9 were much more speciﬁc than D5 for
unoccupied NHR trimers. The mAbs, including a whole IgG 8K8 molecule, neutralized primary HIV-1 of
clades B and C in a pseudotyped virus assay with comparable, albeit relatively modest potency. Finally, a
human Fab T3 and a rabbit serum (both non-neutralizing) were able to block binding of D5 and 8K8 to a gp41
NHR mimetic, respectively, but not the neutralizing activity of these mAbs. We conclude from these results
that NHR coiled-coil analogs of HIV-1 gp41 elicit many Abs during natural infection and through
immunization, but that due to limited accessibility to the corresponding region on fusogenic gp41 few can
neutralize. Caution is therefore required in targeting the NHR for vaccine design. Nevertheless, the mAb panel
may be useful as tools for elucidating access restrictions to the NHR of gp41 and in designing potential
improvements to mimetics of receptor-activated Env.
© 2008 Elsevier Inc. All rights reserved.IntroductionA major goal in HIV-1 vaccine research is to develop an immu-
nogen that can elicit neutralizing antibodies (Abs) against diverse
primary isolates of HIV-1 (Klausner et al., 2003; McMichael, 2006;
Srivastava et al., 2005; Zwick and Burton, 2007). HIV-1 neutralizingth Torrey Pines Road (IMM-2),
1 858 784 8360.
l rights reserved.Abs target the envelope glycoprotein (Env) spikes on the surface of
infectious virions, each spike consisting of a relatively labile trimer of
gp120–gp41 heterodimers. Env-based immunogens typically elicit
only sporadic titers of neutralizing Ab against a limited range of viral
isolates (Beddows et al., 2007; Crooks et al., 2007; Grundner et al.,
2005; Kim et al., 2003; Law et al., 2007; McBurney et al., 2007;
Selvarajah et al., 2005; Yang et al., 2001). Such isolate speciﬁc
neutralization is often associated with Abs against gp120 epitopes
that are either variable in sequence (e.g. V1, V2, V3 and V4) or
exposure on trimeric Env (Pantophlet and Burton, 2006; Phogat and
Wyatt, 2007). To elicit Abs of greater breadth and potency, an Env-
171J.D. Nelson et al. / Virology 377 (2008) 170–183based vaccine may need to correctly present conserved sites on Env to
the immune system in a stable and immunogenic format.
Conserved sites on Env that are crucial to host receptor recognition
or viral fusion are difﬁcult targets for vaccine design. The conserved
CD4 binding site on gp120 is recessed amongst more variable
elements (Pantophlet and Burton, 2006), and is the target of only
one described broadly neutralizingmAb, b12 (Burton et al., 1994; Zhou
et al., 2007). The glycan-rich outer face of gp120 is also the target of
just one described broadly neutralizing mAb, 2G12 (Calarese et al.,
2003; Trkola et al., 1996). V3 and the ‘bridging sheet’ on gp120
constitute the binding site for coreceptor (CCR5 or CXCR4) (Huang
et al., 2005), but Abs against these targets are typically weakly neu-
tralizing due to limited epitope exposure on native Env, and steric and
kinetic restrictions post-CD4 engagement (Binley et al., 2004; Hartley
et al., 2005; Labrijn et al., 2003; Reeves et al., 2005). Gp41 is largely
occluded by quaternary interactions within native Env (Chen et al.,
2005; Sougrat et al., 2007; Wyatt and Sodroski, 1998; Zanetti et al.,
2006; Zhu et al., 2006), although the neutralizing mAbs 2F5, Z13e1
and 4E10 against the membrane-proximal external region (MPER) in
the C-terminal portion of the gp41 ectodomain (Muster et al., 1993;
Nelson et al., 2007; Stiegler et al., 2001) can bind Env and block a late
stage of fusion (Dimitrov et al., 2007; Zwick, 2005). Despite great
effort, high neutralizing Ab titers against any of the conserved sites on
Env have not yet been elicited by design (Kim et al., 2007; Law et al.,
2007; Phogat and Wyatt, 2007).
Post-CD4 engagement, gp41 within Env can rearrange to adopt a
transitional “pre-hairpin” state, in which the fusion peptide inserts
into the host cell membrane (Eckert and Kim, 2001b; Sattentau et al.,
1995). After several minutes and activation of Env by coreceptor, gp41
appears to collapse into energetically stable ‘six-helix bundles’ (6HBs),
thus driving the fusion of virus and host cell membranes (Eckert and
Kim, 2001b; Melikyan et al., 2000). Structures of pre-fusion forms of
gp41 are undetermined, but X-ray and NMR structures of the 6HB core
of gp41 reveal a trimer of N-heptad repeat (NHR) α-helices sur-
rounded by three C-heptad repeat (CHR) helical peptides in an anti-
parallel fashion (Caffrey et al., 1998; Chan et al., 1997; Lu et al., 1995;
Weissenhorn et al., 1997). The inner-helical NHR trimer in these 6HB
structures has been used tomodel the receptor-activated state of gp41
and to design several mimetics of the NHR coiled-coil that can po-
tently inhibit fusion. Examples of such NHR trimer mimetics include,
NCCG-gp41 (Louis et al., 2001), N35CCG-N13 (Louis et al., 2003), IZN36
and similar mimetics (Bianchi et al., 2005; Eckert and Kim, 2001a), as
well as "5-helix", a single-chain mimetic in which one CHR peptide ofFig. 1. Binding by ELISA of mAbs against a panel of immobilized gp41 mimetic antigens. MAb
screening process, and (B) a panel of gp41mimetics and peptides. ThemAb concentrations at
binding (b5 nM, dark), moderate binding (5–50 nM, half dark), weak binding (51–330 nM, lig
'Neutralizing', and b, 'Non-neutralizing' were found to neutralize HIV-1HxB2 with an IC 50b1the 6HB is missing so as to expose a long grooved interface of the NHR
coiled-coil (Root et al., 2001).
The CHR peptide, C34 (Chan et al., 1997; Gustchina et al., 2005), as
well as certain other fusion inhibitors, including T-20 (Wild et al.,
1994), D-peptides (Eckert et al., 1999; Welch et al., 2007) and other
peptidomimetics (Jiang et al., 1993; Sia and Kim, 2003) can bind to the
NHR coiled-coil and potently inhibit HIV-1 entry into cells. Access of
fusion inhibitors to the NHR region however appears to be limited, as
CHR peptides that are tethered to cargo proteins tend to lose inhi-
bitory potency with increasing cargo size (Hamburger et al., 2005).
Recently, human mAbs have been identiﬁed from non-immune Fab
phage display libraries that can bind to NHR mimetics, inhibit HIV-1-
mediated fusion (Louis et al., 2005) and neutralize various isolates in a
pseudotyped assay with modest potency (Gustchina et al., 2007;
Miller et al., 2005). An X-ray crystal structure of one mAb, D5, in
complex with the gp41-mimetic, 5-Helix, reveals the D5 Fab arm
binding orthogonally to the axis of the NHR trimer and into a con-
served hydrophobic pocket (Chan, Chutkowski, and Kim, 1998; Luftig
et al., 2006). More recently, Fab 3674 has been identiﬁed, which is
distinguished by its ability to bind tightly not only to the NHR coiled-
coil, but also to a 6HB mimetic in which the NHR and CHR regions are
connected by a six-residue linker (Gustchina et al., 2007). Despite the
interest these fusion inhibitors and mAbs have generated about the
conserved NHR region as a potential vaccine lead, the immunogenic
potential of the NHR coiled-coil has not been well established.
Here, we rescued rabbit and human mAbs speciﬁcally against the
NHR coiled-coil of gp41 from immune phage display libraries. One set of
phage libraries was prepared from b9 rabbits (Popkov et al., 2003) that
had been immunized with the NHR mimetic, N35CCG-N13 (Louis et al.,
2003). N35CCG-N13 encompasses residues 546–575 of gp41, presents
high-afﬁnity binding sites for up to three CHR peptides (Louis et al.,
2003), and includes pocket-forming residues implicated in D5 recogni-
tion (Luftig et al., 2006). A previous study showed that a puriﬁed fraction
of polyclonal rabbit IgG, monospeciﬁc for N35CCG-N13, can block HIV-1
Env-mediated cell fusion with considerable potency (IC50 10–50 nM)
(Louis et al., 2003). We also prepared a Fab phage library using bone
marrow RNA of an HIV-infected individual, FDA2 (Moore et al., 1996;
Parren et al., 1998; Vujcic and Quinnan, 1995). Using a unique afﬁnity-
selection strategy, we isolated rabbit scFvs (e.g. 8K8), aswell as a human
Fab, DN9, that can neutralize different primary isolates of HIV-1 in a
pseudotyped assay. These neutralizing mAbs do not signiﬁcantly re-
cognize soluble gp41 or 6HB and thus were not elicited against im-
munogens structurally related to these proteins. Fab DN9 andmAb 8K8,s were titered in parallel against (A) r-gp41HxB2 and N35CCG-N13, used in the initial mAb
half-maximal binding were determined and are represented using shaded boxes: strong
ht with diagonal line), and no detectable binding (N330 nM, light). MAbs designated as a,
00 nM, and an IC50>~4 μM in a single-round infectivity assay, respectively (see text).
Fig. 2.Heavy and light chain variable region amino acid sequences of human and rabbit anti-NHRmAbs used in this study. The germline genes with closest homology for each of the human heavy and light chain variable regions are also shown
with % homology reported at the protein level.
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Table 1
Neutralization by rabbit scFv 8K8 and human Fab DN9 of pseudotyped clade B, A and C
isolates of HIV-1 in a single-round infectivity assay using U87.CD4.(CXCR4 or CCR5)
target cells
Isolate Clade IC50 (nM)
8K8 scFv DN9 Fab
HXB2 B 30 45
MN B 30 25
ADA B 130 60
YU2 B 150 200
R2 B 250 200
SF162 B 250 nd
JR-FL B N5000 nd
JR-CSF B 500 nd
92UG037.8 A 600 N1000
92RW020.5 A 300 600
92BR025.9 C 250 50
ZM109F.PB4 C 300 100
ZM53M.PB12 C nd 200
SIVmac239 N5000 nd
173J.D. Nelson et al. / Virology 377 (2008) 170–183although currently of limited potency, are nevertheless evidence that
neutralizing Abs can be elicited against the NHR trimer alone. These
mAbs may be useful in probing the HIV-1 fusion mechanism and pre-
screening next-generation immunogens based on the gp41 NHR region.
Results
Identiﬁcation of anti-NHR mAbs from rabbit scFv and human Fab
immune libraries
In an effort to identify neutralizing Abs against the gp41 NHR region,
we explored two different approaches. In the ﬁrst approach, we
followed-up on a study that examined rabbit hyperimmune sera
raised against the gp41-NHR mimetic, N35CCG-N13 (Louis et al., 2003).
N35CCG-N13 is a soluble homotrimer corresponding to the HIV-1 gp41
NHR region residues 546–580 (i.e. SGIVQQQNNLLRAIEAQQHLLQLTVW-
GIKQ-CCG-RISGIVQQQNNLLRA; in which ‘CCG’ replaces residues
576–578 for stabilization of the trimer by disulﬁde formation and
the C-terminal residues repeat the ﬁrst 13 residues). In that study,
serum inhibition of HIV-1 was not readily detected, but a puriﬁed
fraction of the polyclonal IgG that was speciﬁc for N35CCG-N13 could
potently inhibit HIV-1 fusion (Louis et al., 2003). Thus, two b9 allo-
type rabbits were similarly hyperimmunized using N35CCG-N13. The
b9 rabbits are well suited for scFv phage library preparation as they
have a relatively low frequency of unpaired Cys80 in their kappa light
chain variable regions, and can be used to generate diverse and high-
afﬁnity Abs (Popkov et al., 2003). Consistent with the prior study, the
resulting antisera did not neutralize the homologous HIV-1 strain,
HxB2, (IC50b1:10 serum dilution), even though the reciprocal end-
point titers against N35CCG-N13 were N105. Bone marrow and spleen
were harvested from the immunized b9 rabbits, total RNA isolated,
and scFv phage display libraries were prepared (Barbas et al., 2001).
Immobilized N35CCG-N13 was used to afﬁnity-select the rabbit scFv
libraries, and individual clones were screened for binding activity
against N35CCG-N13 and a soluble gp41 ectodomain, r-gp41HxB2. Re-
combinant r-gp41HxB2 corresponds to residues 541–682 of gp41, is
produced in various glycosylated forms in Pichia pastoris, and is
commercially available. N35CCG-N13 binderswere identiﬁed from the
rabbit scFv libraries, designated 13K3, R21 and 8K8 (Fig. 1. (The other
antigens used in Fig. 1B are discussed in a subsequent section.) Only
scFv 8K8 had any neutralizing activity against HIV-1HxB2 (see below).
None of the other rabbit scFvs neutralized HIV-1HxB2 (IC50s N6.6 μM;
data not shown).
In a parallel approach to identify anti-NHR speciﬁcities, we initially
sourced a human Fab phage display library with a modest clonal
diversity of ~107, which had been prepared previously using the bone
marrow RNA extracted from an HIV-1 seropositive individual (Zwick
et al., 2001). The individual, FDA2, has been shown to have relatively
broad neutralizing Ab serum titers against primary HIV-1 (Moore
et al., 1996; Parren et al., 1998; Vujcic and Quinnan, 1995). This human
Fab library yielded several N35CCG-N13 binders, a representative
clone of which, N2 Fab, bound very tightly to N35CCG-N13 as well as to
r-gp41HxB2 (Fig. 1A). We also found that the previously described
human Fab T3 (Binley et al., 1996), as well as the murine IgG NC-1
(Dimitrov et al., 2005; Jiang, Lin, and Lu, 1998) bound similarly tightly
to both N35CCG-N13 and r-gp41HxB2 (Fig. 1A). A control human Fab T2,
which binds to a gp41 ‘cluster I’ epitope near to the immunodominant
loop, bound r-gp41HxB2 but not the other gp41 mimetics, as expected,
due to the absence of the immunodominant loop region in the
mimetics. The human Fabs N2, T2 and T3 did not neutralize HIV-1HxB2
(IC50sN4 μM; data not shown) (Binley et al., 1996), and NC-1 has been
shown to have no detectable inhibitory activity at 1.3 μM (Binley et al.,
1996; Jiang et al., 1998).
Given the initial screening results, inwhich several non-neutralizing
Abs could bind tightly to both N35CCG-N13 and recombinant r-gp41HxB2
but, in which 8K8 recognized only N35CCG-N13, we subsequently em-ployed a “competitive selection” strategy. Thus, an excess of r-gp41HxB2
was added to the input phage prior to afﬁnity-selection against
immobilized N35CCG-N13, so as to block the apparent abundance of
non-neutralizing mAbs that cross-reacted with r-gp41HxB2. For these
selections, a second FDA2 Fab librarywasprepared that has a high clonal
diversity (~1010). With these modiﬁcations, twomore rabbit scFvs were
identiﬁed, designated R3 and R7, which have CDR H3 sequences that
bear signiﬁcant sequence homology with 8K8, although their light
chains are unrelated (Fig. 2). In addition, the larger FDA2 human Fab
library (diversity ~1010) now afforded one unique Fab, designated DN9,
which bound to N35CCG-N13 and not to recombinant r-gp41HxB2
(Fig. 1A). The level of homology to V-region germline genes with
human Fab DN9 was found to be within the range observed with the
other non-neutralizing human Fabs (Fig. 2). Fab DN9 has a long CDR H3
(i.e. 20 residues), as do the non-neutralizing human Fabs (i.e. CDRH3s of
Fabs N2, T2 and T3 are 19, 18 and 19 residues, respectively) (Fig. 2). In
contrast, the rabbit scFvs bearmuch shorter CDRH3s, and the8K8 family
of scFvs have 7-residue H3s with high sequence homology. The H3s of
the non-neutralizing rabbit scFvs R21 and 13K3were 14 and 12 residues
in length, respectively (Fig. 2), which is near average for rabbit H3s
(i.e. 11.6 residues) (Wu, Johnson, and Kabat, 1993).
Neutralization of pseudotyped HIV-1 by scFv 8K8 and Fab DN9
Because scFvs R3 and R7 share similar heavy chain sequences and
binding properties with scFv 8K8 (Figs. 1 and 2) and were further
found to neutralize HxB2 and a select few primary isolates with
similar potency to scFv 8K8 (data not shown), we focused on scFv 8K8
and Fab DN9.We tested scFv 8K8 and Fab DN9 against a panel of HIV-1
(T-cell line adapted ‘TCLA’ strains and primary isolates) in a single-
round infectivity assay using U87.CD4.(CXCR4 or CCR5) target cells
(Bjorndal et al., 1997). (Fab DN9 had to be used sparingly due to poor
production yields.) The IC50s of scFv 8K8 and Fab DN9 were found to
be modest, typically ranging from ~50–500 nM (Table 1), and with no
clear pattern of sensitivity based on the NHR sequences of the viruses
chosen (sequences not shown). However, HIV-1JR-FL appeared to be
completely resistant to scFv 8K8 (IC50 N5 μM). HIV-1JR-FL has a highly
unusual Arg at position 564 in the NHR (b0.4% of 562 group M Envs
from the Los Alamos database; 11-2-07), whereas all other viruses in
the panel have the consensus His at that position. Most of the other
viruses chosen from clades B, A and C were at least modestly sensitive
to neutralization by the two mAbs, revealing a breadth to their
neutralizing activity. Such breadth in neutralizing activity is uncom-
mon among described anti-HIV-1mAbs and unprecedented for a mAb
elicited against an Env mimetic.
Fig. 3. IgG 8K8, Fab DN9 and/or IgG D5 do not recognize HIV-1 Env in typical binding assay formats. Anti-gp41 mAbs were used to probe (A) soluble gp140HxB2(−) in which the furin-
cleavage site is knocked out, and (B) cleavage-competent gp160HxB2(+) freshly liberated from infectious HIV-1HxB2 virions using detergent. In both cases, soluble Env was captured in
microtiter wells using immobilized lectin from Galanthus nivalis, prior to probing the wells with the various mAbs. In addition to the mAbs already described in Fig. 1, IgGs 7B2 and
4E10, against the immunodominant loop andMPER of gp41, respectively, were used in the comparison. (C) Immobilized IgG 8K8 and D5were used in a standard virus capture assay in
the presence or absence of 20 μg/ml soluble CD4 (sCD4), and captured virus quantitated using an in-house p24 ELISA using the irrelevant IgG DEN3 as a negative control, and IgGs X5,
D49 and b12 as positive control mAbs against the coreceptor binding site on gp120, the immunodominant loop on gp41, and the CD4 binding site on gp120, respectively.
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gp41 mimetics
To obtain a broader perspective on the speciﬁcities of the
recovered NHR mAbs, the mAbs were titered side-by-side against
additional gp41 mimetics, including the trimeric NHR coiled-coil
mimetic, IZN36 (Eckert and Kim, 2001a); the single-chain 6HB
mimetic, 6-Helix, as well as its counterpart that lacks one outer CHR
peptide domain, 5-Helix (Root et al., 2001); the unconstrained linear
peptides from the NHR, CHR and MPER regions, N36, C34 and 2031,
respectively; and another NHR trimer mimetic that was synthesized
for this study, designated 265, which bears residues 559–580 of the
gp41 NHR region and therefore lacks the N-terminal 13-residue
segment that is repeated twice in N35CCG-N13. Both the neutralizing
and non-neutralizing NHRmAbs were found to bind tightly to 5-Helix
(Fig.1B). None of the Abs recognized the linear peptides 2031, N36 and
C34, indicating a speciﬁc discontinuous NHR epitope with each mAb.
Interestingly, none of the non-neutralizing mAbs bound to the NHR
coiled-coil mimetic IZN36 (Eckert and Kim, 2001a), 265, or the
unconstrained N36 peptide, but did bind tightly to N35CCG-N13,
indicating a speciﬁc conformational requirement with the non-
neutralizing Abs for N35CCG-N13 recognition. The non-neutralizing
murine mAb NC-1 (Jiang, Lin, and Lu, 1998) had previously been
shown to recognize N35CCG-N13 (Dimitrov et al., 2005), and this was
conﬁrmed here. The results reveal that 265 is the NHR coiled-coil
mimetic with the minimal segment to which only the neutralizing
NHR mAbs still bound tightly (Fig. 1B). A more detailed study of the
binding of the NHR mAbs to 265 and related NHR mimetics is in
progress (FMB, PED; manuscript in preparation).Fig. 4. Competition ELISA using IgGs D5 and 8K8, and Fab DN9 against their biotinylated (Bio)
(middle panel), and Bio-DN9 Fab (right panel) at concentrations previously determined to
5-Helix that were pretreated with various concentrations of competing mAb. Results are plot
competitor.A whole IgG molecule 8K8 was engineered using human constant
IgG domains as a scaffold. The chimeric humanized IgG was found to
bind very strongly to N35CCG-N13, and has a similar antigen-binding
proﬁle as its scFv counterpart, as expected (Fig. 1). In slight contrast to
the scFv 8K8, however, a weak reactivity of IgG 8K8 with recombinant
r-gp41HxB2 and 6-Helix at high concentration was observed. We
speculate that this reactivity is due to an avidity effect enhancing the
binding of the bivalent IgG. IgG 8K8 reactivity with 6-Helix was much
weaker than that observed with IgG D5 (half-maximal binding titer
was ~150-fold stronger for D5; binding curves not shown), even
though both mAbs bound with similarly high titers to IZN36 and
5-Helix (Fig.1B). The scFv 8K8 and FabDN9did not bind signiﬁcantly to
r-gp41HxB2 or 6-Helix (Root, Kay, and Kim, 2001), though D5 did cross-
react signiﬁcantly with 6-Helix and somewhat less sowith r-gp41HxB2,
indicating that 8K8 and DN9 have a strong preference for NHR trimers
that are unoccupied by CHR peptide (Fig. 1).
IgGs 8K8, D5 and Fab DN9 do not recognize Env in typical binding assay
formats
Given the relatively speciﬁc binding requirements of 8K8 and DN9
for a trimeric conﬁguration of the NHR region, these mAbs may not
bind to common soluble forms of Env that are often used in mAb
binding assays. To test this notion, we assayed the ability of IgG 8K8
and Fab DN9 to bind to soluble gp140HxB2(−) in which the furin-
cleavage site had been knocked out, as well as to cleavage-competent
gp160HxB2(+) that had been detergent-liberated from infectious
pseudotyped HIV-1HxB2 virions and captured using immobilized lectin
from Galanthus nivalis. Neither gp140HxB2(−) or detergent-dissociatedcounterparts for recognition of immobilized 5-Helix. Bio-8K8 IgG (left panel), Bio-D5 IgG
generate non-saturating binding signals were added to wells coated with immobilized
ted as a percentage of the maximal ELISA binding signal of the Bio-mAb in the absence of
Fig. 5. The effect of C34 on recognition of NHR mimetics 5-Helix and IZN36 by mAbs in
ELISA. (A) C34 efﬁciently blocks recognition of 5-Helix by IgG 8K8 and Fab DN9, but does
not inhibit IgG D5. (B) C34 efﬁciently blocks recognition of IZN36 by IgG 8K8 and Fab
DN9, but does not inhibit IgG D5. (C) IgG 8K8 and Fab DN9, but not IgG D5, can block
binding of biotinylated (Bio)-C34 to immobilized IZN36. (D) C34 induces recognition of
IZN36 by the non-neutralizing anti-gp41 Abs, Fab T3, Fab N2, murine mAb NC-1, and
rabbit scFv R21 at subnanomolar concentrations.
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Env species were bound tightly by other gp41 mAbs, including Fab T2,
Fab T3, Fab N2, 4E10, 7B2 (against the immunodominant loop; (Moore
et al., 2006) (Figs. 3A and B), as well as by 2F5 and D50 (a murine IgG
against an immunodominant CHR ‘cluster II’ epitope on gp41; (Earl
et al., 1997) (data not shown). NC-1 recognized the gp140HxB2(−) but
not gp160HxB2(+); the structural basis for this discrepancy is not clear.
The above results indicate that the epitopes of 8K8, DN9 and D5 are
occluded with soluble preparations of gp140HxB2(−) and gp160HxB2(+).
In models of HIV-1 Env fusion, the NHR trimer is not yet formed in
the native untriggered form of Env and is available only for a relatively
short period of time post receptor engagement. We attempted to
capture infectious HIV-1HxB2 whole virions using immobilized IgGs
8K8 and D5 in a standard virus capture assay that measures the p24
content of the captured virions (Nyambi et al., 2000; Poignard et al.,
2003), with the expectation that no virus will be captured due to the
absence of the NHR trimer epitopes on the virion surface. Indeed, the
levels of captured HIV-1HxB2 virions (p24) using immobilized IgGs 8K8
and D5 were no different than that using a negative (irrelevant)
control mAb, IgG DEN3, despite efﬁcient virion capture using IgG b12
(against the CD4 binding site of gp120) and IgG D49 (against the
immunodominant loop of gp41) (Fig. 3)C, open bars). The addition of
soluble CD4 (sCD4) did not induce capture of HIV-1HxB2 virions by 8K8
and D5, despite signiﬁcantly enhancing virion capture by IgG X5
(against the coreceptor binding site of gp120) and diminishing capture
by IgG b12 (Fig. 3C, closed bars). These data show that 8K8 and D5
cannot capture HIV-1 virions in the presence or absence of soluble
CD4, indicating that accessibility to their epitopes on virion-associated
Env is at least somewhat restricted.
IgGs 8K8, D5 and Fab DN9 bind to overlapping but distinct epitopes on
NHR coiled-coil mimetics
To further explore the binding properties of 8K8, D5 and Fab DN9
we performed competition experiments.We found that D5was able to
block IgG 8K8 binding to 5-Helix (unidirectionally) though not as
efﬁciently as 8K8 inhibited itself (Fig. 4, ﬁrst two panels). Fab DN9
inhibited and was inhibited by 8K8, but it did not block D5 binding to
5-Helix. IgG 8K8 efﬁciently blocked Fab DN9 binding to 5-Helix, but
did not block D5 (Fig. 4, right panel). These mAb competition experi-
ments show that the speciﬁcities of 8K8 andDN9overlap somewhat, but
are clearly distinct from each other and from D5. Next, we wished to
determine the effect of free C34 peptide on mAb recognition of 5-Helix
and IZN36. Figs. 5A and B show that at high concentrations, C34
efﬁciently blocked recognition of immobilized 5-Helix and IZN36 by Fab
DN9 and IgG 8K8, but not by IgG D5. In reverse format, recognition of
IZN36 by biotinylated C34 could be blocked using IgG 8K8 and Fab DN9,
but not using D5 (Fig. 5C).We conclude that the binding sites of 8K8 and
DN9 overlapmorewith that of C34 thandoes theD5 epitope.We further
observed that low nanomolar concentrations of C34 are sufﬁcient to
induce recognition of IZN36 by the non-neutralizing mAbs Fab T3, Fab
N2, IgG NC-1 and scFv R21 (Fig. 5D). These non-neutralizing mAbs had
no observable reactivity with C34 alone (Fig. 1). The neutralizing mAbs
8K8, DN9 and D5 were therefore unique among the panel of mAbs in
their ability to recognize IZN36 in the absence of C34.
To furtherdistinguish between the epitopes of the neutralizing IgGs
8K8 and D5 and those of other NHR Abs, competition experiments
were performed using 5-Helix as the target antigen and with various
competitors including mAbs, rabbit sera against N35CCG-N13, and the
neutralizing sera of two HIV-1 seropositive individuals, FDA2 (Moore
et al., 1996; Parren et al., 1998; Vujcic and Quinnan, 1995) and LT2
(Dhillon et al., 2007). Of the completely non-neutralizing mAbs,
Fab T3 was able to efﬁciently block D5 but not 8K8 binding to
immobilized 5-Helix (Fig. 6). In contrast, the non-neutralizing poly-
clonal rabbit sera could only block 8K8 binding to 5-Helix. Thus, the
epitopes of 8K8 and D5 on 5-Helix overlap with epitopes of separateand distinct non-neutralizing anti-NHR Abs. Finally, the FDA2 serum
(diluted 1:10) was able to block both IgGs 8K8 and D5, whereas the
LT2 serum only blocked D5, indicating a speciﬁc difference between
the NHR Ab subspeciﬁcities in the sera of these two HIV-1 sero-
positive individuals (Fig. 6).
Neutralization by IgGs 8K8 and D5 is not affected by non-neutralizing
anti-NHR Abs
Because the non-neutralizing sera against N35CCG-N13 block 8K8
binding to 5-Helix, one might argue that a preponderance of non-
Fig. 6. Binding of IgGs 8K8 and D5 to immobilized 5-Helix can be blocked using non-neutralizing anti-NHR sera or mAb in an ELISA. Biotinylated (Bio)-8K8 IgG (left panel) is inhibited
by non-neutralizingαNHR Sera #13 and #8 (drawn fromN35CCG-N13-immunized rabbits) and, to a lesser degree, by a neutralizing serum from patient FDA2. Bio-D5 IgG (right panel)
is inhibited by non-neutralizing anti-NHR Fab T3, and by neutralizing sera from patients LT2 and FDA2. At the highest concentration, the competing sera are added 1:10, and Fab T3
and the negative control mAb DEN3 are each added at 1 μM, and a 5-fold dilution series is performed.
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neutralizing activity of 8K8 and related Abs in the same serum.
However, the same concentrations of these rabbit sera, and of Fab T3,
which efﬁciently block the binding of 8K8 and D5 to 5-Helix,
respectively, have no effect on the neutralization potency of these
mAbs against HIV-1HxB2 (Fig. 7). These data suggest that the non-
neutralizing NHR Abs simply do not recognize the NHR trimer on the
authentic gp41 fusion intermediate, even though they bind tightly to
overlapping epitopes on NHR peptidomimetics.
Neutralization of HIV-1 (clades B and C) using IgGs 8K8, D5 and 4E10
The neutralizing activity of IgG 8K8 was compared with IgGs D5
and 4E10 against a panel of pseudotyped HIV-1, including TCLA and
primary isolates from clades B and C. As expected, all of the HIV-1Fig. 7. Neutralization of HIV-1HxB2 by IgGs 8K8 and D5 in the presence or absence of
non-neutralizing anti-NHR sera or mAb. Virus was pre-incubated for 1 h with
incremental concentrations of IgG 8K8 or IgG D5 in the presence or absence of sera,
Fab T3, or negative control IgG DEN3 (constant concentration of 1:10 for the sera and
1 µM for the mAbs, corresponding to the highest concentrations used in Fig. 6) and then
added to U87.CD4.CXCR4 cells. Luciferase activity was measured after 72 h. (A) IgG 8K8
neutralization in the presence of normal sera (negative control), αNHR sera #13, or
αNHR sera #8. (B) IgG D5 neutralization in the presence of IgG DEN3 (negative control)
or Fab T3.isolates are sensitive to neutralization by the broadly neutralizing
mAb 4E10, which targets a highly conserved epitope on the MPER of
gp41 (IC50s typically ranging from~3–30 nM), and all except HIV-1JR-FL
are at least modestly sensitive to IgG 8K8 (IC50s typically ~200–
1000 nM; Table 2). For the eleven HIV-1 isolates that were tested also
against D5, seven of these were found to be slightly more sensitive to
D5 than to IgG 8K8 (IC50s within a few fold of each other), the
exceptions being HIV-1ADA and HIV-1YU2 that were more sensitive to
8K8, and HIV-1JR-FL, which was completely resistant to IgG 8K8
(Table 2). As a whole, these data show that IgG 8K8 has cross-clade
HIV-1 neutralizing activity in a single-round infectivity assay, which
approximates to the breadth and potency of IgG D5, but is typically 1
or 2 orders of magnitude less potent than IgG 4E10, depending on the
isolate.
NHR Ala substitutions that confer resistance or hypersensitivity to
neutralization by IgG 8K8
We also performed neutralization assays using IgGs 8K8 and D5
against a series of four mutants of pseudotyped HIV-1LAI, each engi-
neered to bear a single Ala substitution in the NHR region. The fusion
inhibitor drug T-20 (enfuvirtide) was also included as a positive
control in the comparison. Two of the mutants, H564A and L565A,
were chosen based upon the resistant isolate HIV-1JR-FL, which has
two uncommon residues at these positions (i.e. R564 and M565). The
other two mutants, L568A and K574A, reportedly confer resistance to
neutralization by IgG D5 (Miller et al., 2005). As suspected, the H564ATable 2
Neutralization of pseudotyped clade B and clade C primary isolates of HIV-1 by IgGs
8K8, D5 and 4E10 in a single-round infectivity assay using U87.CD4.(CXCR4 or CCR5)
target cells
Isolate Clade IC50 (nM)
8K8 IgG D5 IgG 4E10 IgG
HXB2 (TCLA) B 40 30 b1
ADA B 150 170 3
YU2 B 100 270 4
SF162 B 470 200 3
JR-FL B N3300 2600 30
JR-CSF B 800 200 20
ZM197M.PB7 C 1200 1000 8
Du172 C 500 200 10
CAP45.2.00.G3 C 50 nd 15
CAP210.2.00.E8 C 500 500 8
ZM214M.PL15 C 1000 800 10
ZM109F.PB4 C 400 400 4
ZM53M.PB12 C 1100 nd 330
SIVmac239 N3300 N3300 N3300
Fig. 8.MAb binding to cardiolipin using a standardized ELISA format (Harris et al., 1994).
Assayed mAbs include the gp41 IgGs 8K8, D5, 4E10 and a described cardiolipin cross-
reactive mAb CL15 (Hwang et al., 2001).
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increase in IC50), indicating that H564 is critical for 8K8 recognition of
the gp41 NHR region. The L565A substitution however made the virus
~10–20-foldmore sensitive to 8K8 and D5 as well as T20 (Table 3). The
L568A and K574A mutants, which are reportedly 19-fold and 11-fold
more resistant to D5 (Miller et al., 2005), were found in our hands to
be about N10-fold and 2-fold more resistant to D5, respectively
(Table 3). Interestingly, neutralization sensitivity to 8K8 was less
affected by these D5 resistance mutations (2-fold change or less). The
L565A, L568A and K574A mutants, but not H564A, were slightly more
sensitive to T-20, perhaps due to slower fusion kinetics with the
former three Ala-mutants, as the former mutants, but not the latter,
were less infectious than wt HIV-1LAI, and similar mutations re-
portedly can affect both fusion kinetics and T20 sensitivity (Miller
et al., 2005; Reeves et al., 2002). In general, the neutralization
sensitivity proﬁles of 8K8, D5 and T-20 against the four NHR Ala
mutant viruses were distinct, suggesting a difference in the binding
mechanisms for each Ab/inhibitor.
IgGs 8K8 and D5 do not cross-react with cardiolipin
A recent study has suggested that the difﬁculty in eliciting broadly
neutralizing Abs against HIV-1 may be due to down regulation of
cognate B-cells that are autoreactive to host antigens, such as car-
diolipin (Haynes et al., 2005; Scherer et al., 2007), although this
mechanism is controversial (Scherer et al., 2007; Vcelar et al., 2007).
We considered whether the apparently low serum titers of 8K8-like
antibodies in rabbits that had been immunized with N35CCG-N13
could be due to cross-reactivity of such Abs with cardiolipin. In an
ELISA that has been used in a multicenter study for determining
cardiolipin cross-reactivity, we observed no binding to cardiolipin
with IgGs 8K8 and D5, under conditions in which binding was clearly
observed with the previously described cardiolipin cross-reactive
mAb CL15 (Hwang et al., 2001), and to a lesser extent 4E10 (Fig. 8).
Thus, cardiolipin cross-reactivity is not an explanation for the poor
titers of the 8K8 speciﬁcity in the sera of N35CCG-N13-immunized
rabbits, nor is it a general phenotype for neutralizingmAbs against the
NHR region of gp41.
Discussion
This study providesmAb evidence of HIV-1 neutralizing speciﬁcities
generated (i) in animals by immunization using a gp41 NHR mimetic
protein, and (ii) in natural HIV-1 infection in humans. The successful
identiﬁcation of neutralizing Abs against the NHR region depended on
the use of the stable, helical NHR gp41-mimetic, N35CCG-N13 (Louis
et al., 2003). For example, the selection of the human Fab DN9 appearedTable 3
Relative neutralization sensitivities of NHR Ala-mutants of pseudotyped HIV-1LAI to IgG
8K8, T20 and IgG D5 in the single-round infectivity assay using U87.CD4.CXCR4 target
cells
HIV-1LAI clone Infectivitya Fold-resistance [(IC50mutant)/
(IC50wt)]
8K8 T20 D5
LAI (wild type) ++ 1 1 1
H564A ++ N30 1 1
L565A + 0.05 0.1 0.05
L568A + 0.5 0.3 N10, 19b
K574A + 1 0.2 2, 11b
a Infectivity of Ala mutant pseudoviruses relative to parental HIV-1LAI as measured by
relative light units (RLU) produced in target cells by viral supernatants. ++, infectivity
similar to that of wild-type HIV-1LAI; +, infectivity between≈6–20% that of wild-type.
b D5 data taken from ref.(Miller et al., 2005) for comparison (performed using the
closely-related strain HxB2).to require an initial selection round using N35CCG-N13, followed by the
competitive selection strategy involving high concentrations of recom-
binant r-gp41HxB2. In contrast, Fab DN9 was not identiﬁed in parallel
selections using IZN36, against which Fab DN9 binds very tightly (our
unpublished observations). We presume that co-selection of non-
neutralizing speciﬁcities in the ﬁrst round of afﬁnity-selection was
beneﬁcial for subsequent enrichmentof the rare neutralizing FabDN9 in
later competitive selection rounds.
The antigen-binding and mAb-competition experiments using
8K8, DN9 and D5 strongly suggest that the epitopes of 8K8 and DN9
are more closely related to each other than to that of D5. Although D5
has a reported preference to bind NHRmimetics in the absence of CHR
peptide (Luftig et al., 2006; Miller et al., 2005), our experiments
indicate signiﬁcant cross-reactivity of D5 with immobilized 6-Helix.
Similarly, C34 competes efﬁciently with 8K8 and DN9 binding to
immobilized NHR mimetics (e.g. 5-Helix and IZN36), but not with D5
in our experiments. Recently, a novel Ab, Fab 3764, has been shown to
bind to the NHR region with approximately equally high afﬁnity
whether free (cf. N35CCG-N13) or interacting with CHR peptide in the
form of a 6HB (cf. the minimal stable ectodomain core of gp41 and
NCCG-gp41) (Gustchina et al., 2007). Given our observation that C34
also induces non-neutralizing epitopes on IZN36 at very low
concentrations, determining the minimal requirements of neutraliza-
tion activity for NHR mAbs will be required before mimetics of the
NHR region that include the CHR region can be considered as vaccine
candidates.
The afﬁnity of the NHR region for CHR peptide has been largely
attributed to the N-terminal portion of the NHRwhereas the afﬁnity of
the NHR for itself has been ascribed to the C-terminal portion of the
NHR that includes the hydrophobic pocket (Chang and Hsu, 2007;
Dwyer et al., 2003). Given the strong competition between 8K8/DN9
and C34, these mAbs might bind N-terminal to Fab 3764, which is
unaffected by N–C interactions. We would further argue that DN9 and
8K8 contact two adjacent NHR helices simultaneously, similar to C34.
In support of this notion, Western blot analysis revealed that IgG 8K8
recognized only NHR trimer constructs and not the 6HB, and therefore
behaved like a ‘class C’ Ab, as deﬁned in an earlier study (Louis et al.,
2005; JML, CAB, GMC, unpublished observations). More precise
structural details of the 8K8 and DN9 epitopes can be determined
using crystallography to shed light on the observed differences in the
functional epitopes amongst our mAbs and Fab 3674 and D5.
HIV-1 natural infection elicits many non-neutralizing mAbs
against various epitope clusters on gp41, making it difﬁcult to identify
and distinguish these from neutralizing ones. Non-neutralizing anti-
gp41 mAbs have been mapped to the disulﬁde loop region, the NHR
region proximal to this loop, and the CHR region adjacent to the MPER
(Binley et al., 1996; Earl et al., 1997; Opalka et al., 2004; Xu et al., 1991).
The binding of many of thesemAbs to gp41 has been shown to depend
on the coiled-coil association of the NHR and CHR regions (Chen et al.,
2000; Gorny and Zolla-Pazner, 2000; Jiang et al., 1998; Xu et al., 1991).
We also identiﬁed non-neutralizing mAbs (rabbit and human) against
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are clearly distinct from the non-neutralizing epitopes described
above, as DN9 and 8K8 do not bind tightly to soluble r-gp41HxB2,
gp140, or gp160, as many non-neutralizing mAbs do. We also found
that immobilized IgGs 8K8 and D5 are unable to capture infectious
HIV-1 virions in the presence or absence of soluble CD4, in contrast to
that observed with many non-neutralizing mAbs to gp41 that bind to
gp41 from which gp120 has been shed, or to gp41 within non-
functional gp41–gp120 heterodimers (Burrer et al., 2005; Moore et al.,
2006; Nyambi et al., 2000; Poignard et al., 2003). The fact that 8K8
binding to 5-Helix is blocked by both DN9 and D5, the latter of which
binds to the hydrophobic pocket on the NHR coiled-coil (Luftig et al.,
2006), together with the observation that all three mAbs bind to the
relatively short NHR trimer mimetic 265, links these neutralizing anti-
NHR speciﬁcities to a relatively restricted region of the NHR near to
the hydrophobic pocket. Although the non-neutralizing Fab T3 can
block D5 from binding to 5-Helix, Fab T3 likely lacks neutralizing
activity because it cannot bind to fusogenic NHR trimers. Indeed, we
found that Fab T3 only recognizes IZN36 if it is pre-complexed with
C34, which would in turn, mimic the 6HB (post fusion) form of gp41.
Fab T3 has further been shown unable to bind to native Env trimers
(i.e. [gp120–gp41]3) in a Blue-native PAGE gel-mobility shift assay
(Moore et al., 2006). Further clariﬁcation of the precise epitope of Fab
T3 may be useful in determining the exact features of the NHR coiled-
coil that are accessible to Ab solely on fusogenic gp41, as the T3
epitope is apparently accessible on N35CCG-N13 but not on IZN36.
With respect to DN9, it would seem unlikely that the antigen that
elicited this speciﬁcity in vivowould have been the bona ﬁde fusogenic
‘pre-hairpin’ gp41, due to its apparent limited stability and exposure,
but may have been an antigenically related form of gp41, which might
have originated on the surface of virus, infected cells, or as soluble
debris.
Several possible explanations may account for the inability of many
anti-NHR Abs to neutralize HIV-1. (i) Part(s) of the NHR region that are
distal to the hydrophobic pocket may be occluded by intermolecular
interactions within functional Env, by membrane, and/or by host cell
receptors. (ii) The angle of approach of the Abs to their epitope, rather
than the precise epitope surface they recognize, may preclude access of
anti-NHRAbs to the fusion intermediate. Indeed, post CD4-engagement,
steric restrictions to the NHR have been demonstrated previously
(Hamburger et al., 2005). (iii) Subtle differences in secondary, tertiary or
quaternary structure may exist between the authentic fusion inter-
mediate and the cognate regions on gp41 NHR mimetics. (iv) Kinetic
restrictions may limit the period in which Abs can bind to the fusion
intermediate, especially those with slow on-rates and fully reversible
binding mechanisms (Dimitrov et al., 2005; Steger and Root, 2006).
The neutralization potency of D5 has been reported to be roughly
equivalent, on a molar scale, among its whole IgG, Fab and single-
chain Fv (scFv) counterparts (Miller et al., 2005). In contrast, a bivalent
construct of Fab 3674 was typically, though not always, more potent
than its monovalent counterpart (Gustchina et al., 2007). Other mAbs
have been reported to recognize conformational epitopes on gp41
(gp140), in which there does not appear to be a clear and consistent
effect on neutralization potency between the Fab and IgG formats
(Choudhry et al., 2007; Zhang et al., 2006). Here, we observed that the
neutralization potency of scFv 8K8 and its IgG counterpart were, in the
main, roughly comparable, though the scFv was occasionally more
potent. This ﬁnding is not unexpected given the study by Hamburger
et al., which demonstrated steric blocks surrounding the NHR coiled-
coil that become apparent when C34 is fused with increasingly bulky
fusion partners (Hamburger et al., 2005). Fab DN9 is poorly produced
in E. coli, which limited its use in assays. Hence, a whole IgG DN9 is
under construction, which is expected to produce greater Ab yields
and facilitate future structure–function studies with this mAb.
The neutralization potencies of IgGs 8K8 and D5 were broadly
similar, although D5 was able to neutralize HIV-1JR-FL, which 8K8could not. The result with HIV-1JR-FL may be explained by the rare
R564 residue in JR-FL, which replaces the more commonly observed
H564 that is so critical for 8K8 neutralization as shown by the Ala-scan
analysis. We note that the resistance of HIV-1JR-FL to NHR-targeted
anti-HIV-1 mAbs and inhibitors has been previously reported, and
may relate to the kinetics of fusion, another structural feature of the
NHR region in JR-FL, or some combination of these factors (Gustchina
et al., 2007; Miller et al., 2005; Welch et al., 2007). An Ala-scan study
involving soluble NHR coiled-coils is in progress to determine the
relative contributions of different side-chains to anti-NHR mAb
recognition (manuscript in preparation, FMB, PED). It is noteworthy
that the IC50s with IgG D5 in our study are several-fold lower than
those reported in an earlier study using D5 (Miller et al., 2005). The
differences in assay sensitivity may be due, at least in part, to
differences in coreceptor density on target cells that reportedly can
affect the neutralization potency of mAbs and inhibitors, particularly
those that may be sensitive to fusion kinetics (Choudhry et al., 2006;
Ketas et al., 2007; Reeves et al., 2005). Nevertheless, in both the Merck
D5 study and in our own, the MPER mAb controls (i.e. 2F5 and 4E10,
respectively) were found to be more potent than the anti-NHR mAbs
by ~1–2 orders of magnitude and sometimes more. As we found in a
prior study involving weaker neutralization with resistant isolates of
HIV-1 (Zwick et al., 2005), the shape of neutralization curveswith IgGs
D5 and 8K8 can make IC50 determinations more difﬁcult than with
more potent mAbs.
There is no doubt that the moderate potency of the described anti-
NHR mAbs, being about 1 to 2 orders of magnitude weaker than IgG
4E10, is a major concern with respect to any approach to vaccine
design involving this region. Nevertheless, 8K8 and DN9 showmodest
but relatively broad neutralization that includes isolates from clades B
and C, which is an uncommon phenotype. Moreover, the described
NHR mAbs may not reﬂect the potency of all Abs in their class. More
potent anti-NHR Abs might exist given that a monospeciﬁc fraction of
rabbit polyclonal IgG against the NHR mimetic, N35CCG-N13, inhibited
fusion more potently than 2G12 (Louis et al., 2003). The present mAb-
competition data would seem to suggest that the weak neutralization
in the serum of the hyper-immunized rabbit is unlikely to be a
function of non-neutralizing (or enhancing) Abs counteracting the
activity of neutralizing Abs. Rather, our results and the results of Louis
et al. (2003) would suggest that the poor neutralizing activity in the
serum is mainly due to relatively low titers of Abs that can recognize
the gp41 fusion intermediate.
Finely elucidating the steric and kinetic access restrictions to the
NHR region will presumably be beneﬁcial to drug and vaccine design.
If the steric restrictions derive from Env itself, thesemay be opportune
surfaces against which other drugs or more potent neutralizing Abs
may be sought. Immunogen design must consider the presentation of
the NHR region with the permissible geometry of Ab approach, and
the close apposition of the target cell membrane prior to fusion. The
parameters of binding kinetics can be addressed in part using
mutagenesis and afﬁnity optimization of existing mAbs (Steger and
Root, 2006). With respect to drug design, the NHR mimetics
themselves, while extremely potent (Bianchi et al., 2005; Louis et al.,
2001, 2003), are very likely to be highly immunogenic in vivo, which
may signiﬁcantly diminish their potential as therapeutics (we found,
for example, that non-neutralizing sera against N35CCG-N13 can block
the anti-HIV-1 activity of N35CCG-N13; RJ, MBZ, unpublished observa-
tions). Thus, the effects of immunogenicity of NHR mimetics on
vaccine design and therapeutic design are reciprocal in nature and
must be dealt with accordingly. Therapeutically, a small molecule
inhibitor of the NHR region would therefore be preferable, providing
that sufﬁcient potency and breadth of activity can be reached in vivo.
It is unclear in the present rabbit study whether the apparent
immunodominance of non-neutralizing Abs against N35CCG-N13 may
have been exacerbated by clonotypic dominance of pre-existing B-cell
pools. The absence of detectable cardiolipin reactivity with 8K8
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Scherer et al., 2007), cannot explain the weak titers of 8K8-like Abs in
the rabbits. However, the heavy chain variable regions of the
neutralizing scFvs (i.e. 8K8, R3, R7) were clearly clonally related and
encoded by a rarely expressed VH gene (X32), whereas those of non-
neutralizing scFvs were encoded by the usually expressed VH1a1
(13K3) or VH1a2 (R21). Importantly, our data suggest that if the NHR
mimetic does not accuratelymimic the fusogenic target on HIV-1, then
non-neutralizing anti-NHR Abs may inhibit the elicitation of potential
neutralizing Abs to adjacent epitopes. MAbs against both neutralizing
and non-neutralizing epitopes on existing NHRmimetics may therefore
be useful in pre-screening second generation immunogens in vitro, prior
to initiating immunization experiments. In addition, three-dimensional
structural information of the mAb-mimetic complexes may be used to
better predict the accessibility to the NHR on fusogenic gp41 for pro-
spective next-generation therapeutics.
Materials and methods
Materials
The following reagents were obtained from the National Institutes
of Health AIDS Research and Reference Reagent Program (ARRRP)with
contributors in square brackets: pNL4-3.Luc.R-E- (Connor et al., 1995)
[N. Landau], U87.CD4 (CCR5+ or CXCR4+) cells (Bjorndal et al., 1997)
[H. Deng and D. Littman], Env complementation plasmids [F. Gao,
B. Hahn, L. Morris, D. Monteﬁori, S.A. Karim, G. Ramjee, Y. Li, J.F.
Salazar-Gonzalez, K. Mlisana, E. Hunter and C. Derdeyn], N36 and C34
peptides [DAIDS, NIAID]. The gp160MN-encoding plasmid was kindly
provided by J. Moore and S. Beddows (Cornell). All other Env-
complementation plasmids have been described: HxB2, YU2, ADA, JR-
FL and JR-CSF (Sullivan et al., 1998; Zwick et al., 2003); R2 [G. Quinnan]
(Quinnan et al., 1999; Zwick et al., 2003); pCAGGS SF162 gp160 [L.
Stamatatos and C. Cheng-Mayer] (Cheng-Mayer et al., 1997; Stamatatos
et al., 2000). The gp41 NHR peptidomimetic and fusion inhibitor IZN36
(Eckert and Kim, 2001a) was kindly provided by D. Eckert (Merck). The
plasmids encoding 5-Helix and 6-Helix (Root et al., 2001) were gen-
erously provided by M. Root (TJU); the cognate proteins were produced
in E. coli, and puriﬁed using Ni-NTA chromatography (Qiagen),
according to a described method (Root et al., 2001), and found to be
N95% pure by SDS-PAGE. Human IgG 4E10 (Buchacher et al., 1994) was
procured from H. Katinger through the IAVI NAC (R. Pantophlet). IgG D5
(Miller et al., 2005) was a generous gift from M. Miller (Merck). Human
Fabs T2 and T3 (Binley et al., 1996) were produced in E. coli and puriﬁed
using Protein G chromatography. Murine IgG NC-1 (Jiang et al., 1998)
was a kind gift from S. Jiang (NYBC). Anti-cardiolipin antibody CL15
(Hwang et al., 2001) was a generous gift from P. Chen (UCLA) via J.K.
Scott. Recombinant r-gp41HxB2 (aa 541–682) was purchased from Viral
Therapeutics (Ithaca, NY). Serum from the HIV-1 seropositive indivi-
duals, FDA2 (Moore et al., 1996; Parren et al., 1998; Vujcic and Quinnan,
1995) (gift from J. Tavel), and LT2 (Dhillon et al., 2007), were from blood
drawn on 2-9-05 and in 2005, respectively.
Immunization of b9 rabbits
An immunization procedure similar to that of Louis et al was
followed (Louis et al., 2003). Brieﬂy, two b9 allotype-deﬁned rabbits,
(ZZ135-5 and 2ZZ8-5 both heterozygous VH1a1/a2 and homozygous
b9k; “13” and “8”), housed at the NIAID rabbit facility (Spring Valley
Laboratories, Woodbine, MD), were immunized using 250 μg N35CCG-
N13 in complete Freunds adjuvant, and boosted 4 times every 3 weeks
with 200 μg N35CCG-N13 in incomplete Freunds adjuvant. The rabbits
were sacriﬁced 5 days after the ﬁnal boost in which the serum ELISA
endpoint titers against immobilized N35CCG-N13 were N1:105, and the
spleens and bone marrow harvested. The tissues were immediately
placed in TRI reagent (Sigma) and frozen at −80 °C.Preparation of rabbit scFv and human Fab phage libraries
Rabbit libraries
Rabbit single-chain (sc) Fv (VL–VH) libraries were prepared
according to a previously described method (Barbas et al., 2001).
Brieﬂy, total RNA was prepared separately from the bone marrow and
spleen of the two b9 rabbits using the TRI reagent (Sigma). First-strand
cDNA was prepared from the total RNA using Superscript III
(Invitrogen), and the cDNA used in PCR reactions using Expand High
Fidelity polymerase (Roche) and Ab speciﬁc primers to amplify Vκ, Vλ
and VH genes. Vκ and Vλ PCR products were linked to VH PCR product
using splicing overlap extension PCR employing the long linker (‘LL’,
18 amino acids) and short linker (‘SL’, 7 amino acids), respectively.
Lambda and kappa libraries for each of the two rabbits were sub-
cloned separately into pComb3X (Barbas et al., 2001), though the 8λ
library was discarded due to poor ligation efﬁciency. Library sizes
were between 2–5×107 for the 13κ, 13λ and 8κ libraries.
Human Fab FDA2 library
A human Fab (kappa) library was constructed using the bone
marrow of an HIV-1 seropositive individual, essentially as described
previously (Wild et al., 2003). Brieﬂy, mRNA puriﬁed from the bone
marrow total RNA was extracted using Oligotex mRNA kit (Qiagen),
followed by ﬁrst strand cDNA synthesis using SuperScript II RT First
Strand cDNA Synthesis Kit and oligo (dT) (Invitrogen). Kappa light
chains and IgG Fd fragments were ampliﬁed, as previously described
(Wild et al., 2003). Kappa light chains, followed by the IgG Fd frag-
ments were sequentially cloned into the PAX243 hGK vector. The ﬁnal
FDA IgGκ library size was 1.2×1010.
Afﬁnity-selection of scFvs and Fabs from phage libraries
The scFv rabbit and human FDA2 Fab libraries were each minimally
subjected to a single round of afﬁnity-selection against immobilized
N35CCG-N13 in a 96-well plate (Corning) using established methods
(Barbas et al., 2001). The output scFv phage were was pooled for
subsequent rounds. In an initial selection, four rounds of selection
against N35CCG-N13 were used to identify scFv 8K8. In follow-up se-
lections, an in-solution competition strategy was used to mask non-
neutralizing gp41 epitopes. Thus, rabbit scRvs R3 and R7, as well as a
human Fab DN9were isolated using a single round against N35CCG-N13,
followedby four rounds againstN35CCG-N13 in the presence of an excess
(20 μg/ml) of soluble recombinant r-gp41HxB2 (Viral Therapeutics).
PhagemidDNAwasprepared from the enriched phage pools and used to
transform the non-amber suppressing E. coli strain, Top10 (Invitrogen),
for production of soluble scFv and Fab. Individual colonies were picked
and screened for reactivity in the crude bacterial culture supernatants
against N35CCG-N13 and r-gp41HxB2, and for neutralization of HIV-1HxB2
pseudotyped virus in the single-round infectivity assay. Puriﬁcation of
scFvs and Fabs was achieved using Ni-NTA (Qiagen) and Protein G
chromatography, respectively, as previously described (Barbas et al.,
2001).
Construction and production of chimeric rabbit-human IgG1 8K8
Phagemid DNA encoding 8K8 (scFv) was used as template for
ampliﬁcation of variable heavy (PCR 1) and light (PCR 2) chain regions,
using VH4/VHrev and VK1/VKrev primers, respectively (Barbas et al.,
2001). Human CH1 (PCR 3; primers VHfor and HG33rev) and CK (PCR 4;
RCSF39 and leadB) were appended to the rabbit variable regions using
splicing overlap extension (SOE) PCR and the respective outer primers
(SOE 1). The humanized Fd and kappa chain DNA segments were
sequentially subcloned as XbaI–SacI and HindIII–EcoRI fragments,
respectively, into a mammalian IgG expression vector, pDR12 (Burton
et al., 1994). The pDR12-8K8 DNAwas veriﬁed byDNA sequencing, and
then used with the FuGENE6 transfection reagent (Roche) to transfect
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expanded using methionine sulfoximine (MSX; Sigma) selection and
subjected to limiting dilution. The clone with the highest production
of IgG1 8K8, as determined using enzyme-linked immunosorbent
assay (ELISA) with cell culture supernatant, was chosen for scale-up in
the CellCube System (Corning) and puriﬁed by afﬁnity chromatogra-
phy with protein A (Pharmacia). Puriﬁed IgG1 8K8 was concentrated,
dialyzed against PBS and sterile ﬁltered (0.2 μm). Ab purity (N95%) and
concentrationwas determined using SDS-PAGE, and using absorbance
at 280 nm.
ELISAs
(i) Direct ELISA. Microwells (96-well, half-diameter, high protein
binding; Corning) were coated overnight at 4 °C with 0.2 µg
5-Helix in 50 µl of PBS. The wells were washed twice using PBS
containing 0.05% Tween 20, and blockedwith 4%NFDM(non-fat
drymilk) in PBS for 1 h at 37 °C. Fifty microliters of mAb, diluted
in 0.4% NFDM and 0.02% Tween 20, were added to thewells and
incubated for 2 h at 37 °C. Following incubation, the wells were
washed ﬁve times and a goat-anti-human (Fab′)2-horseradish
peroxidase conjugate (1:1000; Pierce; for human IgGs and Fabs)
or rat anti-HA high afﬁnity-horse radish peroxidase conjugate
(1:1000; Roche; for the HA-tagged rabbit scFvs) was added to
the wells and incubated for 1 h. The wells were washed ﬁve
times and then developed by adding 50 µl of tetramethylbenzi-
dine (TMB) solution (Pierce) according to the manufacturer's
instructions. Wells containing TMB solutionwere stopped after
10 to 20 min before the maximal signals reached an optical
density of 1.8, by adding 50 µl of H2SO4 (0.2 M), and the optical
density at 450 nm was read on a microplate reader (Molecular
Devices).
(ii) Competition ELISA: mAb inhibition of biotinylated mAbs. Micro-
wells were coated with antigen and blocked as above. Twenty-
ﬁve microliters of competitor mAb or sera, diluted in PBS
containing 0.4% NFDM and 0.02% Tween 20, were added to the
wells immediately followed by an equal volume of biotinylated
Ab (ﬁnal concentrations of biotinylated Abs were as follows: for
8K8, 10 ng/ml; for D5, 142 ng/ml; for DN9, 50 ng/ml). Following
a 2-h incubation at 37 °C, the wells were washed ﬁve times, and
a streptavidin–horseradish peroxidase conjugate (1:1000;
Jackson ImmunoResearch) was added to the wells and
incubated for 1 h. The wells were washed, developed and
then read on a microplate reader as described above. Each Ab
competitor was tested in at least two separate experiments
with similar results.
(iii) Competition ELISA: inhibition of mAbs using C34. Microwells
were coated with 5-Helix or IZN36 and blocked as above.
Twenty-ﬁve microliters of C34, diluted in PBS containing 0.4%
NFDM and 0.02% Tween 20 at incremental concentrations, were
added to the wells immediately followed by an equal volume of
Ab. (Final concentrations of Abs for 5-Helix and IZN36,
respectively, were as follows: for 8K8, 80 ng/ml (both antigens);
for D5, 200 and 400 ng/ml; for DN9, 2000 and 80 ng/ml).
Following a 2-h incubation at 37 °C, the wells were washed ﬁve
times, and a goat-anti-human Fab'2-HRP conjugate (1:1000;
Jackson ImmunoResearch) was added to the wells and in-
cubated for 1 h. The wells were washed, developed and then
read, as described above.
(iv) Competition ELISA: inhibition of biotinylated C34 using mAbs.
Microwells were coated with IZN36 and blocked, as above. The
wells were washed twice, and 25 μl of competitor mAb diluted
in PBS containing 0.4% NFDM and 0.02% Tween 20 were added.
In a separate tube, biotinylated C34 (40 nM ﬁnal concentration)
and a streptavidin-peroxidase conjugate (1:1000 ﬁnal concen-
tration; Jackson ImmunoResearch) were pre-complexed for 1 hat 37 °C. Following a brief (15 min) pre-incubation with mAb
competitor in the IZN36-containing wells, the pre-complexed
bio-C34-streptavidin–peroxidase mixture was added directly
to thewells and themixture incubated for a further 1 h at 37 °C.
The wells were washed, developed and then read, as described
above.
(v) Gp140HxB2(−) and gp160HxB2(+) sandwich ELISA. To generate
gp140HxB2(−), a substitution at the furin-cleavage site (i.e.
‘REKR’-N‘REKS’) was introduced using Quikchange mutagenesis
(Stratagene) into the Env-complementation vector (pSVIIIex-
e7pA-HxB2 (Sullivan et al., 1998)). Microwells were coated with
0.25 µg Galanthus nivalis lectin (GNL) and blocked, as above.
Wells were washed twice and 50 µl were added of cell culture
supernatant containing either uncleaved gp140HxB2(−), or
infectious HIV-1HxB2 pseudotyped virus (10-fold concentrated)
that was treated with 1% Empigen to dissociate Env, and the
plates incubated for 3 h at 37 °C. Wells were washed ﬁve times
and 50 µl of mAb, diluted in PBS containing 0.4% NFDM and
0.05% Tween 20, were added towells and incubated 2 h at 37 °C.
Wells were washed ﬁve more times and 50 µl goat-anti-human
or anti-mouse (Fab′)2-HRP conjugate (1:1000, Jackson) was
added and incubated for 45 min at room temperature. Wells
were washed ﬁve times and developed with TMB solution and
read on a microplate reader as described above.
(vi) Cardiolipin ELISA. Cardiolipin ELISAs were performed as
previously described (Harris et al., 1994), using Protocol A
(Nelson et al., 2007).
HIV-1 virion capture assay
Pseudotyped HIV-1HxB2 were produced as described below for the
neutralization assays. For virus capture, ELISA microtiter wells were
coated overnight at 4 °C with 5 µg/ml capture mAb in PBS, similar to
methods previously described (Moore et al., 2006; Nyambi et al.,
2000). The wells were blocked with 4% NFDM in PBS for 1 h at 37 °C
and then 50 µl of virus was added and incubated for 3 h at 37 °C. The
wells were washed six times with PBS and captured virus was lysed
with 50 µl 1% Empigen in PBS. Lysed virions were added to microwells
previously coated with sheep-anti-p24 (D7320; Aalto Bioreagents)
and incubated for 3 h at room temperature. Wells were washed 5
times and 50 µl of sheep-anti-p24 alkaline phosphatase conjugate
(Cliniqa) was added for 1 h at room temperature. Wells were
developed using the AMPAK ampliﬁcation kit (Argene) and read at
490 nm.
HIV-1 neutralization assays
Pseudotyped HIV-1, competent for a single round of infection, were
generated by co-transfection of 293Tcells using the luciferase reporter
plasmid pNL4-3.Luc.R-E- (Connor et al., 1995), an Env-complementa-
tion vector, and the PEI transfection reagent (Kirschner et al., 2006), as
described previously (Zwick et al., 2003). In the case of the LAI Env-
complementation vector, the plasmid pcDNA3.1/V5-His-TOPO was
used to subclone LAI env (PCR ampliﬁed using pLAI-2 (Peden et al.,
1991) as template, according to a previously described method (Li
et al., 2005)). HIV-1LAI Ala-mutants were generated using Quikchange
mutagenesis (Stratagene), and veriﬁed by DNA sequencing.
The pseudotyped viruses were assayed for neutralization using
U87.CD4.CCR5 cells (or U87.CD4.CXCR4 cells for HxB2, LAI and MN
viruses) as target cells (Bjorndal et al., 1997). Abs were added to HIV-1
in 100 μl DMEM (Gibco) containing 10% fetal calf serum, and the virus-
Abmixtures incubated for 1 h at 37 °C prior to transferring (1:1 by vol)
to the target cells (ﬁnal vol. 200 μl). In the case of the mAb-serum co-
incubation experiments, IgGs 8K8 and D5were diluted in the presence
of a ﬁxed, excess concentration of polyclonal sera (1:10 ﬁnal dilution)
or mAbs (1 μM ﬁnal concentration), respectively. Following a 72-h
181J.D. Nelson et al. / Virology 377 (2008) 170–183incubation at 37 °C, the cells were lysed, luciferase reagent (Promega)
added, and the luminescence in relative light units (RLUs) was
measured using an Orion microplate luminometer (Berthold Detec-
tion Systems). The extent of virus neutralization was determined as a
percentage reduction of viral infectivity against that of an Ab-free
control. All experiments were performed in triplicate.
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